聚二磷酸腺苷核糖聚合酶抑制剂治疗结直肠癌的研究进展  

Progress of poly(ADP-ribose)polymerase inhibitors in treatment of colorectal cancer

作　　者：宋明瀚 邵丽娟 陈斯泽 Song Minghan;Shao Lijuan;Chen Size(Department of Immuno-Oncology,the First Affiliated Hospital of Guangdong Pharmaceutical University,Guangzhou 510080,China;Key Laboratory of Cancer Immunotherapy of Guangdong Higher Education Institutes,Guangzhou 510080,China;Guangdong Provincial Engineering Research Center for Esophageal Cancer Precision Therapy,Guangzhou 510080,China)

机构地区：[1]广东药科大学附属第一医院肿瘤免疫科,广州510080 [2]广东省普通高校肿瘤免疫治疗重点实验室,广州510080 [3]广东省食管癌精准治疗工程技术研究中心,广州510080

出　　处：《肿瘤研究与临床》2024年第2期153-156,共4页Cancer Research and Clinic

基　　金：国家自然科学基金(32271225)。

摘　　要：结直肠癌恶性程度高,尽管在化疗基础上采用靶向药物治疗提高了疗效,晚期结直肠癌患者预后仍较差。聚二磷酸腺苷核糖聚合酶(PARP)抑制剂作为第一个协同致死机制类靶向药物,在同源重组缺陷的卵巢癌、乳腺癌中应用广泛,取得较好的临床效果。近些年来,随着二代测序技术的进步和精准靶向治疗日渐成熟,越来越多的临床试验开始探索PARP抑制剂在结直肠癌中的应用。文章阐述了PARP抑制剂治疗结直肠癌的相关分子机制及几种联合PARP抑制剂治疗方案在结直肠癌领域的应用,以期为晚期结直肠癌治疗提供新思路。Colorectal cancer is a highly malignant disease characterized by a poor prognosis.Although the targeted therapy based on chemotherapy improves the efficacy,the prognosis of advanced colorectal cancer patients is poor.Poly(ADP-ribose)polymerase(PARP)inhibitors,which act through a synergistic lethal mechanism,have been widely utilized in treating ovarian and breast cancer cases with homologous recombination deficiency and have demonstrated positive clinical outcomes.Recently,due to advancements in next-generation sequencing technology and the development of precision targeted therapy,an increasing number of clinical trials have started to investigate the potential of PARP inhibitors in colorectal cancer treatment.This review summarized the molecular mechanism of PARP inhibitors in the treatment of colorectal cancer and the application of several combined PARP inhibitors therapy regimens in colorectal cancer,in order to provide new insights for the treatment of colorectal cancer.

关 键 词：结直肠肿瘤 聚二磷酸腺苷核糖聚合酶抑制剂 同源重组修复缺陷 治疗结果 

分 类 号：R735.34[医药卫生—肿瘤]